NCT07227597 2026-02-20
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
3 trialsNCT06030258 2025-04-30
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT05745350 2025-02-11
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting